Open access
Aug 2026
CA 15.3, Metastatic Burden, and Overall Survival in Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer: Real-World Evidence from Peru
Elevated baseline CA 15.3 was associated with greater metastatic burden and shorter OS, and baseline/follow-up patterns were exploratory because the sampling was not standardized, and should be interpreted as an adjunct to clinical and radiological assessment.
Guillermo Valencia, P. Rioja, Jessica Meza et al.
· Biomedicines · 0 citations